Physician profile
Robert Eugene Nelson
NPI 1972696037
$2,157,008.63
in general payments reported to CMS, 2019-2025
28 companies · $392K in 2025
The $392K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230K · 2020: $192K · 2021: $254K · 2022: $322K · 2023: $358K · 2024: $409K · 2025: $392K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $851K · Consulting Fee: $118K · Travel and Lodging: $95K · Honoraria: $60K · Food and Beverage: $35K · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850,638.15 |
| Consulting Fee | $118,361.50 |
| Travel and Lodging | $94,508.14 |
| Honoraria | $60,125.00 |
| Food and Beverage | $34,877.37 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $468,230.53 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $459,394.09 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $411,520.21 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $396,958.15 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $168,674.72 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $159,161.39 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $51,507.68 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21,591.89 | 2019-2025 | Rejoyn |
| Takeda Pharmaceuticals U.S.A., INC. | $15,138.51 | 2019-2024 | Trintellix |
| Eli Lilly and Company | $1,900.00 | 2025 | |
| Lundbeck LLC | $585.41 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $465.18 | 2019-2025 | Ingrezza |
| Abbvie INC. | $441.13 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $311.04 | 2019-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $185.09 | 2019-2024 | Jornay Pm |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $155.73 | 2019-2025 | Spravato |
| Almatica Pharma LLC | $118.66 | 2022-2024 | Loreev Xr, Gralise |
| Allergan, INC. | $112.07 | 2019-2020 | |
| Corium, LLC | $104.96 | 2022-2025 | Azstarys |
| Shire North American Group INC | $91.84 | 2019 | |
| Acadia Pharmaceuticals INC | $84.86 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $79.08 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $45.57 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $43.16 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $42.01 | 2024-2025 | Relexxii |
| Mdd US Operations, LLC | $31.95 | 2019 | |
| Sage Therapeutics, LLC | $18.17 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.